Abstract
Kruppel-like factor 5 (KLF5) belongs to a family of zinc-finger-containing transcription factors which are involved in regulating expression of a wide range of genes, thereby affecting diverse cellular functions. The activities of KLF5 are regulated by multiple signaling pathways including Wnt, Ras, TGFβ, Hippo, Notch, retinoid acid receptor, and hormone receptors. The expression of KLF5 is frequently abnormal in human cancers and the functions of KLF5 are context dependent. Accumulating evidence suggests that KLF5 represents a novel therapeutic target for cancer therapy. In this review, we discuss the potential biological functions of KLF5 associated with several key signaling pathways that are relevant to cancer as well as the involvement of KLF5 in various human cancers. We also describe the progress in the discovery and development of small molecules targeting KLF5 as potential therapeutics that may benefit cancer patients. The challenges and future research directions on the drug discovery of KLF5 ligands are also presented.
Keywords: Kruppel-like factor 5 (KLF5), Transcription factors, Signaling pathways, Cancer therapeutics, KLF5 ligands, Drug discovery.
Current Topics in Medicinal Chemistry
Title:Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy
Volume: 15 Issue: 8
Author(s): Yu Gao, Ye Ding, Haiying Chen, Haijun Chen and Jia Zhou
Affiliation:
Keywords: Kruppel-like factor 5 (KLF5), Transcription factors, Signaling pathways, Cancer therapeutics, KLF5 ligands, Drug discovery.
Abstract: Kruppel-like factor 5 (KLF5) belongs to a family of zinc-finger-containing transcription factors which are involved in regulating expression of a wide range of genes, thereby affecting diverse cellular functions. The activities of KLF5 are regulated by multiple signaling pathways including Wnt, Ras, TGFβ, Hippo, Notch, retinoid acid receptor, and hormone receptors. The expression of KLF5 is frequently abnormal in human cancers and the functions of KLF5 are context dependent. Accumulating evidence suggests that KLF5 represents a novel therapeutic target for cancer therapy. In this review, we discuss the potential biological functions of KLF5 associated with several key signaling pathways that are relevant to cancer as well as the involvement of KLF5 in various human cancers. We also describe the progress in the discovery and development of small molecules targeting KLF5 as potential therapeutics that may benefit cancer patients. The challenges and future research directions on the drug discovery of KLF5 ligands are also presented.
Export Options
About this article
Cite this article as:
Gao Yu, Ding Ye, Chen Haiying, Chen Haijun and Zhou Jia, Targeting Kruppel-Like Factor 5 (KLF5) for Cancer Therapy, Current Topics in Medicinal Chemistry 2015; 15 (8) . https://dx.doi.org/10.2174/1568026615666150302105052
DOI https://dx.doi.org/10.2174/1568026615666150302105052 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Anti-Proliferative Role of the Tyrosine Kinase Inhibitors TKI-258 on Oral Squamous Cell Carcinoma In Vitro
Anti-Cancer Agents in Medicinal Chemistry Different 6-Aryl-Fulvenes Exert Anti-proliferative effects on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology Pharmacogenomics of Xenobiotic Metabolizing Enzymes in South American Populations
Current Pharmacogenomics MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design The Endocannabinoid System and Pain
CNS & Neurological Disorders - Drug Targets Utility and Limitations of SP600125, an Inhibitor of Stress-Responsive c-Jun N-Terminal Kinase
Current Enzyme Inhibition Phase II Drug Metabolism and Individualized Drug Therapy: A Focus on Functional Genetic Variation in UDP-Glucuronosyltransferases
Current Pharmacogenomics and Personalized Medicine Mitochondrial Dysfunction and Targeted Drugs: A Focus on Diabetes
Current Pharmaceutical Design Development of Lymphatic Vessels: Tumour Lymphangiogenesis and Lymphatic Invasion
Current Medicinal Chemistry Role of Radiopharmaceuticals in Development of Inhaled Drugs
Current Pharmaceutical Design CARING (CAncer Risk and INsulin analoGues): The Association of Diabetes Mellitus and Cancer Risk with Focus on Possible Determinants - A Systematic Review and a Meta-Analysis
Current Drug Safety The miRNAs and Epithelial-Mesenchymal Transition in Cancers
Current Pharmaceutical Design Cancer Risk and Nullity of Glutathione-S-Transferase Mu and Theta 1 in Occupational Pesticide Workers
Current Pharmaceutical Biotechnology Impact of Cellular Senescence in Aging and Cancer
Current Pharmaceutical Design Endometriosis and Gynecological Cancer
Current Women`s Health Reviews Patent Selections:
Recent Patents on Anti-Cancer Drug Discovery Head and Neck Cancer Treatments through Chemotherapy to Magnetic Systems: Perspectives and Challenges
Current Radiopharmaceuticals Labelling and Tracking of Human Mesenchymal Stromal Cells in Preclinical Studies and Large Animal Models of Degenerative Diseases
Current Stem Cell Research & Therapy